114 related articles for article (PubMed ID: 37633993)
1. CRTAC1 enhances the chemosensitivity of non-small cell lung cancer to cisplatin by eliciting RyR-mediated calcium release and inhibiting Akt1 expression.
Jin Z; Zhao L; Chang Y; Jin R; Hu F; Wu S; Xue Z; Ma Y; Chen C; Zheng M; Chang Y; Jin H; Xie Q; Huang C; Huang H
Cell Death Dis; 2023 Aug; 14(8):563. PubMed ID: 37633993
[TBL] [Abstract][Full Text] [Related]
2. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1.
Deng H; Qianqian G; Ting J; Aimin Y
Biomed Pharmacother; 2018 Oct; 106():1072-1081. PubMed ID: 30119173
[TBL] [Abstract][Full Text] [Related]
3. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
4. Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway.
Mei Y; Liu YB; Hu DL; Zhou HH
Int J Biol Sci; 2018; 14(13):1859-1872. PubMed ID: 30443189
[TBL] [Abstract][Full Text] [Related]
5. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
6. CACNA2D3 Enhances the Chemosensitivity of Esophageal Squamous Cell Carcinoma to Cisplatin via Inducing Ca
Nie C; Qin X; Li X; Tian B; Zhao Y; Jin Y; Li Y; Wang Q; Zeng D; Hong A; Chen X
Front Oncol; 2019; 9():185. PubMed ID: 31001468
[TBL] [Abstract][Full Text] [Related]
7. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin.
Lee MW; Kim DS; Min NY; Kim HT
Int J Cancer; 2008 May; 122(10):2380-4. PubMed ID: 18224693
[TBL] [Abstract][Full Text] [Related]
8. Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy.
Ma Y; Yuwen D; Chen J; Zheng B; Gao J; Fan M; Xue W; Wang Y; Li W; Shu Y; Xu Q; Shen Y
Int J Nanomedicine; 2019; 14():8121-8132. PubMed ID: 31632022
[TBL] [Abstract][Full Text] [Related]
9. Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study.
Baghbani E; Noorolyai S; Rahmani S; Shanehbandi D; Shadbad MA; Aghebati-Maleki L; Mokhtarzadeh A; Brunetti O; Fasano R; Silvestris N; Baradaran B
Biomed Pharmacother; 2022 Jan; 145():112370. PubMed ID: 34862113
[TBL] [Abstract][Full Text] [Related]
10. The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.
Hu C; Zhang M; Moses N; Hu CL; Polin L; Chen W; Jang H; Heyza J; Malysa A; Caruso JA; Xiang S; Patrick S; Stemmer P; Lou Z; Bai W; Wang C; Bepler G; Zhang XM
Cell Death Dis; 2020 May; 11(5):328. PubMed ID: 32382008
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1.
Cheng R; Lu C; Zhang G; Zhang G; Zhao G
Oncol Rep; 2017 Apr; 37(4):2129-2136. PubMed ID: 28350100
[TBL] [Abstract][Full Text] [Related]
12. KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma.
Wang B; Jing T; Jin W; Chen J; Wu C; Wang M; Liu Y
J Exp Clin Cancer Res; 2020 Aug; 39(1):170. PubMed ID: 32854746
[TBL] [Abstract][Full Text] [Related]
13. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC
Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715
[TBL] [Abstract][Full Text] [Related]
14. Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR-497-5p/mTOR.
Hou Z; Wang Y; Xia N; Lv T; Yuan X; Song Y
Cancer Sci; 2021 Jan; 112(1):275-286. PubMed ID: 33179318
[TBL] [Abstract][Full Text] [Related]
15. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
16. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.
Tian Y; Zhang J; Yan S; Qiu L; Li Z
Lung Cancer; 2012 Jun; 76(3):416-22. PubMed ID: 22137560
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
[TBL] [Abstract][Full Text] [Related]
18. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
Wang F; Lou JF; Cao Y; Shi XH; Wang P; Xu J; Xie EF; Xu T; Sun RH; Rao JY; Huang PW; Pan SY; Wang H
Exp Mol Med; 2015 May; 47(5):e162. PubMed ID: 25952770
[TBL] [Abstract][Full Text] [Related]
19. High Platelet Levels Attenuate the Efficacy of Platinum-Based Treatment in Non-Small Cell Lung Cancer.
Wang Z; Fang M; Li J; Yang R; Du J; Luo Y
Cell Physiol Biochem; 2018; 48(6):2456-2469. PubMed ID: 30121639
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of microRNA-196a enhances the sensitivity of non-small cell lung cancer cells to cisplatin treatment.
Li Q; Yang Z; Chen M; Liu Y
Int J Mol Med; 2016 Apr; 37(4):1067-74. PubMed ID: 26936095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
